ESMO: Obesity Does Not Interfere with Trastuzumab Response (CME/CE)

posted on Oct 10 by MedPage Today OB/Gyn in the Uncategorized category MILAN (MedPage Today) -- Obesity is known to be a risk factor for breast cancer and death in postmenopausal women -- but a small study found that obesity does not seem to hamper the response to trastuzumab (Herceptin) therapy in women with metastatic breast cancer.